Search Results - "SHALINSKY, D. R"

Refine Results
  1. 1

    Phase I trial of SU14813 in patients with advanced solid malignancies by Fiedler, W., Giaccone, G., Lasch, P., van der Horst, I., Brega, N., Courtney, R., Abbattista, A., Shalinsky, D.R., Bokemeyer, C., Boven, E.

    Published in Annals of oncology (01-01-2011)
    “…Background: This phase I, open-label, dose-escalation study investigated SU14813, an oral multitargeted tyrosine kinase inhibitor, in adults with solid tumors…”
    Get full text
    Journal Article
  2. 2

    Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials by SHALINSKY, D. R., BREKKEN, J., ZOU, H., MCDERMOTT, C. D., FORSYTH, P., EDWARDS, D., MARGOSIAK, S., BENDER, S., TRUITT, G., WOOD, A., VARKI, N. M., APPELT, K.

    Published in Annals of the New York Academy of Sciences (01-06-1999)
    “…We studied AG3340, a potent metalloproteinase (MMP) inhibitor with pM affinities for inhibiting gelatinases (MMP‐2 and ‐9), MT‐MMP‐1 (MMP‐14), and…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Rapid vascular regrowth in tumors after reversal of VEGF inhibition by Mancuso, Michael R, Davis, Rachel, Norberg, Scott M, O'Brien, Shaun, Sennino, Barbara, Nakahara, Tsutomu, Yao, Virginia J, Inai, Tetsuichiro, Brooks, Peter, Freimark, Bruce, Shalinsky, David R, Hu-Lowe, Dana D, McDonald, Donald M

    Published in The Journal of clinical investigation (01-10-2006)
    “…Inhibitors of VEGF signaling can block angiogenesis and reduce tumor vascularity, but little is known about the reversibility of these changes after treatment…”
    Get full text
    Journal Article
  5. 5

    Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro by JEKUNEN, A. P, CHRISTEN, R. D, SHALINSKY, D. R, HOWELL, S. B

    Published in British journal of cancer (01-02-1994)
    “…Taxol, a unique tubulin active agent, was found to demonstrate a marked schedule-dependent synergistic interaction with cisplatin (DDP) in the killing of human…”
    Get full text
    Journal Article
  6. 6

    Marked Antiangiogenic and Antitumor Efficacy of AG3340 in Chemoresistant Human Non-Small Cell Lung Cancer Tumors: Single Agent and Combination Chemotherapy Studies by SHALINSKY, D. R, BREKKEN, J, ZOU, H, BLOOM, L. A, MCDERMOTT, C. D, ZOOK, S, VARKI, N. M, APPELT, K

    Published in Clinical cancer research (01-07-1999)
    “…Effective therapy is needed to improve the survival of patients with advanced lung cancers. We studied the effects of a selective metalloprotease inhibitor,…”
    Get full text
    Journal Article
  7. 7

    Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice by SHALINSKY, D. R, BISCHOFF, E. D, GREGORY, M. L, LAMPH, W. W, HEYMAN, R. A, HAYES, J. S, THOMAZY, V, DAVIES, P. J. A

    Published in Clinical cancer research (01-03-1996)
    “…Cisplatin (DDP) is commonly used to treat head and neck tumors. Therapy frequently fails due to development of DDP resistance or toxicities associated with DDP…”
    Get full text
    Journal Article
  8. 8

    Retinoid-induced suppression of squamous cell differentiation in human oral squamous cell carcinoma xenografts (Line 1483) in athymic nude mice by SHALINSKY, D. R, BISCHOFF, E. D, THOMAZY, V, GREGORY, M. L, GOTTARDIS, M. M, HAYES, J. S, LAMPH, W. W, HEYMAN, R. A, SHIRLEY, M. A, COOKE, T. A, DAVIES, P. J. A

    Published in Cancer research (Chicago, Ill.) (15-07-1995)
    “…Retinoids are promising agents for therapy of squamous cancers. In vitro, retinoids decrease expression of differentiation markers in head and neck squamous…”
    Get full text
    Journal Article
  9. 9

    Regulation of initial vinblastine influx by P-glycoprotein by SHALINSKY, D. R, JEKUNEN, A. P, ALCAREZ, J. E, CHRISTEN, R. D, KIM, S, KHATIBI, S, HOWELL, S. B

    Published in British journal of cancer (01-01-1993)
    “…P-glycoprotein (PGP) is an energy-dependent efflux pump that serves to protect cells against the cytotoxicity of many natural product drugs including…”
    Get full text
    Journal Article
  10. 10

    The efficacy of 9-cis retinoic acid in experimental models of cancer by GOTTARDIS, M. M, LAMPH, W. W, SHALINSKY, D. R, WELLSTEIN, A, HEYMAN, R. A

    Published in Breast cancer research and treatment (01-01-1996)
    “…9-cis retinoic acid (9-cis RA) is a retinoid receptor pan-agonist that binds with high affinity to both retinoic acid receptors (RARs) and retinoid X receptors…”
    Get full text
    Conference Proceeding Journal Article
  11. 11

    A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice by SHALINSKY, D. R, BISCHOFF, E. D, LAMPH, W. W, ZHANG, L, BOEHM, M. F, DAVIES, P. J. A, NADZAN, A. M, HEYMAN, R. A

    Published in Cancer research (Chicago, Ill.) (1997)
    “…We have identified a novel retinoid, ALRT1550, that potently and selectively activates retinoic acid receptors (RARs). ALRT1550 binds RARs with Kd values of…”
    Get full text
    Journal Article
  12. 12

    Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations by SHALINSKY, D. R, BREKKEN, J, ZOU, H, KOLIS, S, WOOD, A, WEBBER, S, APPELT, K

    Published in Investigational new drugs (1998)
    “…Oral administration of AG3340, a novel metalloprotease (MMP) inhibitor, suppresses the growth of human colon adenocarcinoma (COLO-320DM) tumors in vivo (Proc…”
    Get full text
    Journal Article
  13. 13

    Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin by Christen, R D, McClay, E F, Plaxe, S C, Yen, S S, Kim, S, Kirmani, S, Wilgus, L L, Heath, D D, Shalinsky, D R, Freddo, J L

    Published in Journal of clinical oncology (01-12-1993)
    “…We developed a new formulation of progesterone that permits administration of up to 10 g of progesterone as a continuous intravenous infusion over 24 hours and…”
    Get more information
    Journal Article
  14. 14

    In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules by CHRISTEN, R. D, JEKUNEN, A. P, JONES, J. A, THIEBAUT, F, SHALINSKY, D. R, HOWELL, S. B

    Published in The Journal of clinical investigation (01-07-1993)
    “…We have previously shown that forskolin and 3-isobutyl-1-methylxanthine (IBMX) increased accumulation of cisplatin (DDP) in DDP-sensitive 2008 human ovarian…”
    Get full text
    Journal Article
  15. 15

    HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors by Johnston, James B., Zhang, Kunyan, Silva, Claudia, Shalinsky, David R., Conant, Katherine, Ni, Weimin, Corbett, Dale, Yong, Voon Wee, Power, Christopher

    Published in Annals of neurology (01-02-2001)
    “…The release of potentially neurotoxic molecules by HIV‐infected brain macrophages is accompanied by neuronal injury and death that results in the development…”
    Get full text
    Journal Article
  16. 16

    Modulation of vinblastine sensitivity by dipyridamole in multidrug resistant fibrosarcoma cells lacking mdr1 expression by SHALINSKY, D. R, SLOVAK, M. L, HOWELL, S. B

    Published in British journal of cancer (01-10-1991)
    “…We examined the ability of dipyridamole (DPM) to act synergistically with vinblastine (VBL) in HT1080 fibrosarcoma cells and a drug-resistant variant,…”
    Get full text
    Journal Article
  17. 17

    Selective modulation of vinblastine sensitivity by 1,9-dideoxyforskolin and related diterpenes in multidrug resistant tumour cells by SHALINSKY, D. R, HEATH, D. D, JEKUNEN, A. P, ALCARAZ, J. E, HOWELL, S. B

    Published in British journal of cancer (01-03-1993)
    “…The ability of 1,9-dideoxyforskolin (DDF), 1-deoxyforskolin (DF) and forskolin to modulate cellular sensitivity to vinblastine (VBL) was examined in…”
    Get full text
    Journal Article
  18. 18

    Inhibition of GSH-dependent PGH2 isomerase in mammary adenocarcinoma cells by allicin by Shalinsky, D R, McNamara, D B, Agrawal, K C

    Published in Prostaglandins (01-01-1989)
    “…We have reported that allicin, a constituent of garlic oil, has no effect on the activities of platelet cyclooxygenase or thromboxane synthase, or vascular…”
    Get more information
    Journal Article
  19. 19

    Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide by Lindnér, P, Heath, D D, Shalinsky, D R, Howell, S B, Naredi, P, Hafström, L

    Published in Surgical oncology (1993)
    “…Intraperitoneal (i.p.) administration of chemoterapeutic agents results in greater total drug exposures in the peritoneal cavity than in plasma. A study on the…”
    Get more information
    Journal Article
  20. 20

    Modulation of prostaglandin biosynthesis in hypoxic murine mammary adenocarcinoma cells by misonidazole by SHALINSKY, D. R, MCNAMARA, D. B, AGRAWAL, K. C

    Published in Cancer research (Chicago, Ill.) (15-07-1989)
    “…Resistance of hypoxic cells to radiation and chemotherapy remains a major limitation to effective therapy of solid tumors. Misonidazole, a 2-nitroimidazole…”
    Get full text
    Journal Article